Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;40(5):1950-1972.
doi: 10.1002/med.21676. Epub 2020 May 23.

Advances in drug development for targeted therapies for glioblastoma

Ge Yan  1   2 , Yunfu Wang  2 , Jincao Chen  1 , Wenzhong Zheng  1 , Changzhen Liu  1 , Shi Chen  1   2 , Lianrong Wang  1   2 , Jie Luo  2 , Zhiqiang Li  1
Affiliations
Review

Advances in drug development for targeted therapies for glioblastoma

Ge Yan et al. Med Res Rev. 2020 Sep.

Abstract

Glioblastoma is the most aggressive primary brain tumor in adults. The prognosis of patients with primary glioblastoma treated with the current standard of care, tumor resection followed by radiation therapy and auxiliary temozolomide, remains poor. Integrative genomic analyses have identified essential core signaling pathways and frequent genetic aberrations, which provide potential drug targets for glioblastoma treatment. Drugs against these therapeutic targets have been developed rapidly in recent years. Although some have shown promising effects on models in preclinical studies, many have shown only modest efficacy in clinical trials. New therapeutic strategies and potent drugs are urgently needed to improve the prognosis of patients with glioblastoma. The goal of this review is to summarize the current advances in drug development for targeted glioblastoma therapies and to reveal the major challenges encountered in clinical trials or treatment. This study will provide new perspectives for future studies of targeted therapeutic drug development and provide insights into the clinical treatment of glioblastoma.

Keywords: drug development; glioblastoma; targeted therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

REFERENCES

    1. Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. 2019;21(suppl_5):v1-v100.
    1. Wen PY, Huse JT. 2016 World Health Organization classification of central nervous system tumors. Continuum (Minneap Minn). 2017;23(6, neuro-oncology):1531-1547.
    1. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764-772.
    1. Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
    1. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157-173.

Publication types

LinkOut - more resources